Arrowhead Pharmaceuticals has received an authorization (Notice of Compliance) from Health Canada for Redemplo (plozasiran), which is an siRNA drug.[1][3] Redemplo is approved as an adjunct to diet to lower triglyceride levels in adult patients with familial chylomicron syndrome (FCS) who have failed standard therapies.[1][3] FCS is a rare disease characterized by triglyceride levels 10 to 100 times higher than normal, greatly increasing the risk of acute, recurrent, and potentially fatal pancreatitis.[1][3] Redemplo uses Arrowhead's proprietary TRiM platform to suppress the RNA gene APOC3, an important target for lowering triglycerides in FCS.[1] The authorization is supported by data from the phase 3 PALISADE study, which was randomized, double-blind, and placebo-controlled in adults with clinically or genetically confirmed FCS.[1] The study was conducted at 39 global sites, including 5 in Canada.[1] Redemplo is Canada's first and only approved siRNA drug for FCS that can be administered subcutaneously at home once every three months.[3]